TRDA Q1 2024 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+134.0% YoY

Gross Profit

$59M100.0% margin

Operating Income

$21M35.7% margin

Net Income

$23M39.7% margin

EPS (Diluted)

$0.68

QoQ Revenue Growth

+41.3%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$511M

Total Liabilities

$241M

Stockholders' Equity

$269M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$25M	+134.0%
Gross Profit	$59M	$2M	+2639.6%
Operating Income	$21M	-$6M	+465.3%
Net Income	$23M	-$7M	+452.1%

Revenue Segments

License

$158M100%